MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Boston Therapeutics, Inc. (BTHE) Begins Enrolling Patients In Phase 2b Trial For PAZ320 0 comments
    Nov 12, 2013 2:30 PM | about stocks: BTHE

    Boston Therapeutics announced it has begun enrolling patients in a Phase 2b Trial for its PAZ320 drug today. A total of 24 patients with type 2 diabetes currently being treated with metformin will be administered PAZ320 under double-blind, placebo-controlled conditions. The study is taking place at Centre Hospitalier Robert Bisson, Lisieux, France.

    Study performers will monitor the patients' blood glucose using continuous glucose monitors, and their after-meal blood glucose levels measured using following a test meal. The primary endgoal of the trial is to evaluate the effect of PAZ320 compared to placebo the area under the curve (AUC) of glucose and on insulin levels in the blood for four hours following intake of the meal. Metformin is the most widely prescribed drug for diabetes, as well as the first drug often prescribed to new patients diagnosed with diabetes.

    David Platt, Ph.D., Chief Executive Officer, BTHE, said, "This trial is designed to build upon the positive results from our Dartmouth Medical Center Phase 2a trial for PAZ320, recently published in the peer-reviewed journal, Endocrine Practice. In the Phase 2a study, PAZ320 was well tolerated in patients taking various anti-diabetic agents, including metformin. The Phase 2b trial, which focuses on patients taking only metformin, is the next step in the investigation of this compound as a potential adjunct to metformin in patients living with Type 2 diabetes. We believe it is important to better control glucose levels throughout the day, given the many complications that stem from uncontrolled diabetes."

    PAZ320 is a non-systemic, non-toxic, chewable drug for prevention of diabetes and its complications. It targets enzymes that digest sugar during digestion, thereby reducing the amount of available glucose for the intestine to absorb. According to the American Diabetes Association, 25.8 million children and adults in the United States have diabetes, of which 27% of that population remains undiagnosed.

    For more information, visit: bostonti.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: BTHE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.